Rep. David Taylor Sells Amgen Inc. (NASDAQ:AMGN) Stock

Representative David Taylor (R-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on December 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on December 3rd. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 12/3/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 11/12/2025.
• Purchased $1,001 – $15,000 in shares of RPM International (NYSE:RPM) on 11/11/2025.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/11/2025.
• Sold $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 11/3/2025.
• Purchased $1,001 – $15,000 in shares of Installed Building Products (NYSE:IBP) on 11/3/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 11/3/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/3/2025.
• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 10/30/2025.

Amgen Stock Down 1.0%

AMGN traded down $3.08 during trading on Tuesday, reaching $318.15. 474,151 shares of the stock were exchanged, compared to its average volume of 2,743,722. The stock has a market cap of $171.32 billion, a P/E ratio of 24.56, a price-to-earnings-growth ratio of 2.98 and a beta of 0.45. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.38. The stock’s 50 day moving average price is $314.36 and its two-hundred day moving average price is $297.78. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter last year, the company posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 annualized dividend and a dividend yield of 3.0%. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares of the company’s stock, valued at $2,436,703.50. The trade was a 30.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the sale, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 10,908 shares of company stock worth $3,674,966. Corporate insiders own 0.69% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in AMGN. MRP Capital Investments LLC bought a new stake in shares of Amgen in the third quarter valued at about $181,000. Saranac Partners Ltd acquired a new stake in Amgen in the 3rd quarter worth about $37,000. Severin Investments LLC boosted its holdings in Amgen by 83.2% in the 3rd quarter. Severin Investments LLC now owns 1,902 shares of the medical research company’s stock valued at $537,000 after purchasing an additional 864 shares during the period. IFP Advisors Inc grew its position in shares of Amgen by 8.6% during the 3rd quarter. IFP Advisors Inc now owns 8,032 shares of the medical research company’s stock worth $2,318,000 after purchasing an additional 638 shares in the last quarter. Finally, Swiss Life Asset Management Ltd increased its holdings in shares of Amgen by 2.3% during the third quarter. Swiss Life Asset Management Ltd now owns 271,340 shares of the medical research company’s stock worth $76,572,000 after purchasing an additional 6,082 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on AMGN. Scotiabank started coverage on Amgen in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target on the stock. Raymond James Financial began coverage on Amgen in a research note on Wednesday, September 3rd. They set a “market perform” rating for the company. Wall Street Zen lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Sunday. Morgan Stanley cut their price target on Amgen from $333.00 to $329.00 and set an “equal weight” rating for the company in a report on Wednesday, November 5th. Finally, Weiss Ratings raised shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $335.65.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.